Cannabinoid hyperemesis syndrome in pregnancy: Challenges and opportunities

Aust N Z J Obstet Gynaecol. 2023 May 31. doi: 10.1111/ajo.13714. Online ahead of print.

ABSTRACT

Antenatal cannabis consumption is common and associated with adverse perinatal outcomes, including low birthweight, pre-term birth and increased rates of admission to neonatal intensive care. Cannabinoid hyperemesis syndrome (CHS) comprises severe, cyclical episodes of vomiting, intractable nausea and abdominal pain observed in chronic cannabis users. CHS, particularly during pregnancy, poses a diagnostic dilemma with a tendency to be ineffectively managed secondary to reduced clinician awareness and a scarcity of available therapies. This clinical perspective explores the current literature on CHS in pregnancy, available pharmacotherapeutics, and recognises the current barriers to improving clinical care.

PMID:37259610 | DOI:10.1111/ajo.13714